2021 Annual Meeting On-Demand: Cellular Therapy/Biotherapies Sessions


Interested in all sessions Cellular Therapy/Biotherapies? Then this is the package for you. We have also thrown in a couple of additional sessions you might also find interesting.

The package includes 22 sessions (1 in Spanish with English subtitles available) which provide you the opportunity to earn up to 16 continuing medical education credits for physicians; 23 general credit, or, 23 California Lab Personnel, Florida Lab Personnel or California Nurse contact hours.

Purchase of this package includes the on-demand recording and a downloadable MP3 audio file (in the original recorded language) for each session. Closed captioning in Spanish and English is also available for most sessions. Some speaker handouts may be available, but in general, presentation handouts are not available/included.

If purchasing these sessions separately it would cost $430/$535 (member/nonmember).

Access is available through December 31, 2023 so purchase this package today.

Planning Committee Disclosures

Standard: $249.00
Members: $199.00

Products

AM21-03: Challenges in Apheresis Cellular Collections during the COVID-19 Pandemic

Preview Available

AM21-03: Challenges in Apheresis Cellular Collections during the COVID-19 Pandemic

Oct 17, 2021 11:15am ‐ Oct 17, 2021 12:15pm

Credits: None available.

The field of cellular therapy has become increasingly complicated in all aspects, including technical, patient, environment, and regulatory. For example, the logistics of apheresis collection as well as the utilization of fresh stem cell product have changed significantly during the current COVID-19 pandemic. In this session, different logistical solutions that apheresis collection facilities have used during the pandemic will be discussed. New regulatory requirements introduced during the COVID-19 pandemic will be reviewed (e.g new FDA guidance) and how these can be implemented into routine operations will be discussed.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s): Speaker(s):
Members: $20.00
Standard: $25.00

AM21-11: El Desarrollo De Terapia Celular En Latino América (Cellular Therapy Development in Latin America)

Preview Available

AM21-11: El Desarrollo De Terapia Celular En Latino América (Cellular Therapy Development in Latin America)

Oct 17, 2021 3:45pm ‐ Oct 17, 2021 4:45pm

Credits: None available.

This educational session is a continuation of the topics presented in the CT Spanish sessions at the 2019 and 2020 AABB annual meetings. This time will focus on Latin America and its development in the field of CT. Initially the history of cell therapy in the world will be discussed with an emphasis on the introduction of this field in Latin American markets. These markets will be discussed by country, describe their development and acting position. Regulation of advanced therapy products in Latin America will also be discussed and barriers to the development of these therapies will be identified. The CT Spanish Subsection will utilize their monthly meetings as a platform to engage with AABB members and obtain up to date information related to their respective countries and their development. The results of our meetings & research, as well as the experiences shared by the speakers will be presented. This will only be in Spanish.

Esta sesión educativa es una continuación de los temas presentados en las sesiones de Terapia Celular (TC) sección en Español en las reuniones anuales de la AABB de los años 2019 y 2020. Esta vez se centrará en América Latina y su desarrollo en el campo de la TC. Inicialmente la historia de la TC en el mundo se discutirá con énfasis en la introducción de este campo en los mercados latinoamericanos. Estos mercados serán discutidos por país, describirán su desarrollo y posición de actual. También se discutirá la regulación de estos productos en América Latina y se identificarán barreras para el desarrollo de estas terapias. La Subsección de Terapia Celular en Español de utilizará sus reuniones mensuales como plataforma para interactuar con los miembros de la AABB y obtener información actualizada relacionada con sus respectivos países y su desarrollo. Se presentarán los resultados de nuestros encuentros e investigaciones, así como las experiencias compartidas por los ponentes. Esta sesión se celebrará en su totalidad en el idioma español.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s): Speaker(s):
Members: $20.00
Standard: $25.00

AM21-15: Pediatric Cellular Therapy: An Overview from Collections to Alpha/Beta Depletions

Preview Available

AM21-15: Pediatric Cellular Therapy: An Overview from Collections to Alpha/Beta Depletions

Oct 17, 2021 6:00pm ‐ Oct 17, 2021 7:00pm

Credits: None available.

Pediatric advanced therapies are an exciting, complex and evolving field. Autologous collections require collaboration between flexible apheresis services and the clinical/research team for success, including quality and reducing error. Mobilization, collection and processing methods impact the final therapeutic product. For haploidentical hematopoietic cell transplantation, Alpha/Beta T-cell Depletion has transformed the approach to donor selection and significantly expanded availability. A modern approach is sophisticated ex vivo processing of the donor graft to remove those cells most responsible for causing GVHD. This session will present examples and discuss the ongoing therapeutic diversification and development in cellular therapy protocols, which will require international collaboration to improve standardization, efficiency, and quality.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s): Speaker(s):
Members: $20.00
Standard: $25.00

AM21-19: Informatics Tools for Transfusion Support of Hematopoietic Progenitor Cell Transplant Recipients

Preview Available

AM21-19: Informatics Tools for Transfusion Support of Hematopoietic Progenitor Cell Transplant Recipients

Oct 17, 2021 7:15pm ‐ Oct 17, 2021 8:15pm

Credits: None available.

This session will illustrate how to leverage lab information system (LIS) and electronic health record (EHR) tools for communication and control of hematopoietic progenitor cell transplant (HPCT) recipient transfusion needs and will be applicable to multiple lab information and electronic health record systems. The session will also include an introduction to transfusion support for HPCT recipients. Examples of EHR designs will demonstrate how to streamline blood ordering processes to limit frequent addition or removal of special attributes and communicate transfusion needs. We will also present LIS-based solutions to hardwire selection of red blood cell and plasma-containing products based on donor and recipient ABO types and allow for safe electronic crossmatch. Potential software limitations will also be discussed.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s): Speaker(s):
Members: $20.00
Standard: $25.00

AM21-23: Creating the Blood Center Infrastructure for Biotherapies: From Contracts to Collections and Distribution

Preview Available

AM21-23: Creating the Blood Center Infrastructure for Biotherapies: From Contracts to Collections and Distribution

Oct 18, 2021 10:00am ‐ Oct 18, 2021 11:00am

Credits: None available.

Blood Banks and Blood Centers (BB/BC) are playing a key role in the advancement of cell and biotherapies. BB/BC are working with pharmaceutical companies as our community advances these therapies to enhance the quality and safety of patient care. This demand necessitates infrastructure development at BB/BC. In this session the speakers will share experiences from 2 BB/BC. They will share their experiences including (1) contracts and budgets, (2) developing pricing, (3) information technology (IT) needs and challenges for Blood Establishment Computer System (BECS) tracking to integrating International Society of Blood Transfusion (ISBT) requirements and (4) how to track and handle compliance among different companies.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s):
  • Dr. Gay Wehrli, MD, MBA, MSEd, University Hospitals, Samaritan Medical Center and Case Western
Speaker(s):
Members: $20.00
Standard: $25.00

AM21-26: Ethics of Engaging Blood Donors for Cell Therapy (Biotherapy) Collections

Preview Available

AM21-26: Ethics of Engaging Blood Donors for Cell Therapy (Biotherapy) Collections

Oct 18, 2021 11:15am ‐ Oct 18, 2021 12:15pm

Credits: None available.

The need for cell and biotherapy donors is rising. To help meet this demand, blood centers are working to transition regular blood donors to become cell and biotherapy donors. Human subject protection is an important aspect for the donations. In this session some of the ethical challenges related to this recruitment and process will be presented and discussed. Topics include biotherapy donor informed consent, payment and frequency of donation. An ethicist will lead this discussion for a robust question and answer period.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s):
  • Dr. Gay Wehrli, MD, MBA, MSEd, University Hospitals, Samaritan Medical Center and Case Western
Speaker(s):
Members: $20.00
Standard: $25.00

AM21-29: Hot Topic: Cryopreservation of HPCs During a Pandemic

Preview Available

AM21-29: Hot Topic: Cryopreservation of HPCs During a Pandemic

Oct 18, 2021 2:30pm ‐ Oct 18, 2021 3:30pm

Credits: None available.

During this session, attendees will receive an update on current trends in using cryopreservation to support hematopoietic cell transplant (HCT) during a pandemic and a donor registry’s experience in providing centralized cryopreservation services. The speakers will also provide a brief review of the most recent studies on the use of cryopreserved allogeneic grafts.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s):
  • Jeff Wren, National Marrow Donor Program® (NMDP)/Be The Match®
Speaker(s):
Members: $20.00
Standard: $25.00

AM21-32: Incorporating Clinical Cellular Therapy Laboratory Education Experiences into Graduate Medical Education (GME) Training

Preview Available

AM21-32: Incorporating Clinical Cellular Therapy Laboratory Education Experiences into Graduate Medical Education (GME) Training

Oct 18, 2021 3:45pm ‐ Oct 18, 2021 4:45pm

Credits: None available.

Clinical cell therapy laboratories (CTLs) that minimally manipulate products are part of many transfusion medicine (TM) services overseen by CTL medical directors with graduate medical education (GME) training in clinical pathology (CP) and/or blood banking and transfusion medicine (BB/TM). Educational experiences combining clinical CTL staff, medical director, and quality and regulatory team perspectives can provide a well-rounded approach for potential future medical directors of clinical CTLs or TM services handling existing and developing cell therapies in the clinical realm. The success and trajectory of established and novel cell therapies and nature of CP and BB/TM training to prepare medical directors underscores the importance of including formal and dedicated educational CTL experiences in CP and BB/TM training programs. This session will highlight the importance of and considerations for incorporating clinical CTL education into post-graduate medical training programs.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator & Speaker(s): Speaker(s):
Members: $20.00
Standard: $25.00

AM21-38: Crucial Conversations about Structural Racism, Equitable Access to Healthcare and Social Justice: Creation of a Multidisciplinary Task Force for Action

Preview Available

AM21-38: Crucial Conversations about Structural Racism, Equitable Access to Healthcare and Social Justice: Creation of a Multidisciplinary Task Force for Action

Oct 19, 2021 11:15am ‐ Oct 19, 2021 12:15pm

Credits: None available.

The emergence of the COVID-19 pandemic and its disproportionate impact on communities of color uncovered the deeply embedded structural racism that exists in the U.S. The pandemic, coupled with the highly visible murder of George Floyd that shocked the collective global consciousness, exposed the reality that structural racism and bias are global issues. We are now called to enter into deliberate dialogue about white privilege, power sharing dynamics, opening access to medical education for communities of color and delivering equitable solutions regarding the social determinants of health. With these objective in mind, in June 2020, the Academy of Integrative Health and Medicine (AIHM) successfully created The Black, Indigenous and People of Color (BIPOC) Task Force to have a role in leading this dialogue and building a coalition of diverse individuals, organizations and institutions to address these needs.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator & Speaker(s): Speaker(s):
Members: $20.00
Standard: $25.00

AM21-39: Optimization of Progenitor Cell Sources for Hematopoetic Cell Transplantation

Preview Available

AM21-39: Optimization of Progenitor Cell Sources for Hematopoetic Cell Transplantation

Oct 19, 2021 11:15am ‐ Oct 19, 2021 12:15pm

Credits: None available.

The choice of hematopoietic progenitor cell source for transplantation is determined by multiple factors including the underlying disease (hematologic malignancy vs non-malignant hematologic disorder), conditioning regimen (myeloablative vs reduced intensity), and type of donor. Data from the prospective randomized Blood and Marrow Transplant Clinical Trial Network 0201 trial regarding bone marrow versus peripheral blood stem cell for hematopoietic cell transplantation, the declining quality of bone marrow harvests over the past two decades, and improved prevention of chronic graft versus host disease will be addressed in this context. This presentation will also address quality improvement strategies for the collection of bone marrow and innovative approaches for optimizing progenitor cell collections by apheresis, including the use of novel agents such as plerixafor and chemokine ligand 2 (CXCL2), to enhance progenitor cell yield and maximize donor safety.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator & Speaker(s): Speaker(s):
Members: $20.00
Standard: $25.00